Listed

Celldex Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2011

Filed with the SEC on Nov 3, 2011 and accepted by EDGAR at Nov 3, 2011, 12:48 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2011-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2011-07-01 to 2011-09-30$2.4mus-gaap:Revenues
Revenue9 months2011-01-01 to 2011-09-30$6.8mus-gaap:Revenues
Research and development3 months2011-07-01 to 2011-09-30$8.6mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2011-01-01 to 2011-09-30$22.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2011-07-01 to 2011-09-30−$11.5mus-gaap:OperatingIncomeLoss
Operating income9 months2011-01-01 to 2011-09-30−$31.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2011-07-01 to 2011-09-30$438.0kus-gaap:InterestExpense
Interest expense9 months2011-01-01 to 2011-09-30$1.4mus-gaap:InterestExpense
Net income3 months2011-07-01 to 2011-09-30−$11.8mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Net income9 months2011-01-01 to 2011-09-30−$32.1mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2011-07-01 to 2011-09-30−$0.27us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2011-01-01 to 2011-09-30−$0.85us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2011-07-01 to 2011-09-3044,136,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2011-01-01 to 2011-09-3037,926,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2011-01-01 to 2011-09-30−$26.3mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure9 months2011-01-01 to 2011-09-30$403.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2011-09-30$13.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2011-09-30$64.4mus-gaap:AssetsCurrent
Total assetsAt period end2011-09-30$108.4mus-gaap:Assets
Current liabilitiesAt period end2011-09-30$10.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2011-09-30$27.8mus-gaap:Liabilities
Shareholders' equityAt period end2011-09-30$80.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-11-060466. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.